Evidence map›Paper›PMID 39893086›Full record

ArticleNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2025

Quantitative imaging outperforms No-reflow in predicting functional outcomes in a translational stroke model.

Justine Debatisse, Lucie Chalet, Omer Faruk Eker, Tae-Hee Cho, Guillaume Becker, Océane Wateau, Marlène Wiart, Nicolas Costes, Inés Mérida, Christelle Léon and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Justine DebatisseUniversité Claude Bernard Lyon1, CarMeN Laboratory, INSERM, INRAE, Bât. B13, Groupement Hospitalier Est, 59 Boulevard Pinel, Lyon, France.
Lucie ChaletUniversité Claude Bernard Lyon1, CarMeN Laboratory, INSERM, INRAE, Bât. B13, Groupement Hospitalier Est, 59 Boulevard Pinel, Lyon, France; Olea Medical, La Ciotat, France.
Omer Faruk EkerUniversité Claude Bernard Lyon1, CREATIS, CNRS, INSERM, INSA Lyon, Bât. Blaise Pascal, 7 Avenue Jean Capelle, Villeurbanne 69621, France; Neuroradiology Department, Hospices Civils of Lyon, 69000, Lyon, France.
Tae-Hee ChoUniversité Claude Bernard Lyon1, CarMeN Laboratory, INSERM, INRAE, Bât. B13, Groupement Hospitalier Est, 59 Boulevard Pinel, Lyon, France; Neuroradiology Department, Hospices Civils of Lyon, 69000, Lyon, France; Stroke Department, Hospices Civils of Lyon, 69000, Lyon, France.
Guillaume BeckerUniversité Claude Bernard Lyon1, CarMeN Laboratory, INSERM, INRAE, Bât. B13, Groupement Hospitalier Est, 59 Boulevard Pinel, Lyon, France.
Océane WateauCynbiose SAS, Marcy-L'Etoile, France.
Marlène WiartUniversité Claude Bernard Lyon1, CarMeN Laboratory, INSERM, INRAE, Bât. B13, Groupement Hospitalier Est, 59 Boulevard Pinel, Lyon, France.
Nicolas CostesCERMEP - Imagerie du Vivant, Lyon, France.
Inés MéridaCERMEP - Imagerie du Vivant, Lyon, France.
Christelle LéonUniversité Claude Bernard Lyon1, CarMeN Laboratory, INSERM, INRAE, Bât. B13, Groupement Hospitalier Est, 59 Boulevard Pinel, Lyon, France.
Jean-Baptiste LangloisCERMEP - Imagerie du Vivant, Lyon, France.
Sophie LancelotCERMEP - Imagerie du Vivant, Lyon, France; Department of Radiopharmacy, Hospices Civils of Lyon, 69000, Lyon, France.
François LuxUniversite Claude Bernard Lyon1, Institut Lumière Matière, CNRS, France.
Timothé BoutelierOlea Medical, La Ciotat, France.
Norbert NighoghossianUniversité Claude Bernard Lyon1, CarMeN Laboratory, INSERM, INRAE, Bât. B13, Groupement Hospitalier Est, 59 Boulevard Pinel, Lyon, France; Neuroradiology Department, Hospices Civils of Lyon, 69000, Lyon, France; Stroke Department, Hospices Civils of Lyon, 69000, Lyon, France.
Laura MechtouffUniversité Claude Bernard Lyon1, CarMeN Laboratory, INSERM, INRAE, Bât. B13, Groupement Hospitalier Est, 59 Boulevard Pinel, Lyon, France; Neuroradiology Department, Hospices Civils of Lyon, 69000, Lyon, France; Stroke Department, Hospices Civils of Lyon, 69000, Lyon, France.
Emmanuelle Canet-SoulasUniversité Claude Bernard Lyon1, CarMeN Laboratory, INSERM, INRAE, Bât. B13, Groupement Hospitalier Est, 59 Boulevard Pinel, Lyon, France. Electronic address: emmanuelle.canet-soulas@univ-lyon1.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Microvascular dysfunction and no-reflow are considered a major cause of secondary damage despite revascularization in acute ischemic stroke (AIS), ultimately affecting patient outcomes. We used quantitative PET-MRI imaging to characterize early microvascular damages in a preclinical non-human primate model mimicking endovascular mechanical thrombectomy (EVT). During occlusion, PET perfusion and MRI diffusion were used to measure ischemic and lesion core volumes respectively. Following revascularization, multiparametric PET-MRI included perfusion, diffusion, blood-brain barrier (BBB) permeability MRI, and

Indexed as

Ischemic StrokeNo-Reflow PhenomenonStrokeAnimalsCerebrovascular CirculationDisease Models, AnimalMagnetic Resonance ImagingMalePositron-Emission TomographyTranslational Research, BiomedicalAcute ischemic strokeBlood-brain barrierNo-reflowOxygen metabolismPET-MRIThrombectomy

Identifiers

PMID39893086
PMCPMC12014402

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.